Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on X about a recent article by Martin Wermke et al. published in Journal of Clinical Oncology:
“New hope in DLL3+ NETs
Phase 1 obrixtamig (BI 764532), a DLL3 x CD3 shows encouraging results in pretreated SCLC, epNEC and LCNEC.
- ORR: 28%
- LCNEC-L ORR: 70%
- Median DoR: 8.5 mo
- CRS: Mostly low-grade and reversible
New player in the DLL3 race!”
Title: Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas
Authors: Martin Wermke, Valentina Gambardella, Yasutoshi Kuboki, Enriqueta Felip, Miguel Sanmamed, Olatunji Alese, Cyrus Sayehli, Edurne Arriola, Jürgen Wolf, Liza Villaruz, Julia Bertulis, Matus Studeny, Mohamed Bouzaggou, Xiaoyan Fang, Daniel Morgensztern
Read the Full Article on Journal of Clinical Oncology
More posts featuring Aakash Desai.
